[[PAGE:1]]

PLAYBOOK OVERVIEW

Medical affairs rollout for the authorised product in EU NSCLC: align field medical with label-first messaging.

[[PAGE:2]]

BOUNDARY CASES

Adjuvant and post-resection discussions remain outside approved scope unless label updates. Keep DRUG-B and DRUG-C narratives separate from DRUG-A.